Company: RCUS
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001724521-25-000052
Chunk: 50

Company: Arcus Biosciences, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 50
---
 evident in the advancement of our clinical programs involving casdatifan, domvanalimab and quemliclustat, all in or near Phase 3 registrational trials. Ms. Jarrett’s leadership and efforts on the corporate development and the medical affairs fronts, both strategic and tactical, led to a key new collaboration with AstraZeneca around our HIF-2a inhibitor casdatifan and to data disclosures that generated strong investigator enthusiasm that will facilitate enrollment in our broad clinical program for this molecule. She has also led our early preparatory efforts to be ready to launch and commercialize our initial product candidates, particularly in working with Gilead to prepare for the potential launch of the domvanalimab/zimberelimab combination therapy. She also was central in negotiating the Gilead equity investment in January 2024 and Hercules term loan facility that extended our cash runway into mid-2027.

Equity Incentives

We believe that equity grants provide our executives with a strong link to our long-term performance, create an ownership culture and help to align the interests of our executives and our stockholders. Therefore, equity awards represent the largest at-risk component of our executive compensation program.

For our 2024 annual equity awards, the Compensation Committee approved awards of $7.5 million, $3.0 million, $3.0 million and $2.1 million for Dr. Rosen, Dr. Jaen, Ms. Jarrett and Mr. Goeltz, respectively. These awards were approved at the Compensation Committee's meeting in the first quarter of 2024 following completion of our annual performance review process. We do not time the grant of our equity awards to be in advance of the announcement of any material information. In determining the aggregate value of the equity awards granted to our executive officers, the Compensation Committee considers a number of factors, including corporate and individual performance, current equity holdings and their retention value and total ownership, historical value of our stock, internal equity amongst executives and market data provided by Radford.

For our 2024 annual equity awards, our Compensation Committee determined that the appropriate mix for equity grants to our executive officers be split, with approximately 67% of the value delivered in the form of stock options and 33% of the value delivered in the form of RSUs. The Compensation Committee believes that this equity mix helps to ensure long-term performance and strong alignment with our stockholders’ interests because their value predominantly depends on future stock price appreciation. Including RSUs also promotes retention and